Who Pays My Doctor?

Healthcare provider profile · identity verified

Charles Joseph Lane, MD

Allopathic & Osteopathic Physicians|Allergy & Immunology · LYNCHBURG, VA · NPI 1699983353

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Charles Joseph Lane, MD received $261,435.73 in general payments during 2025 across 401 reported records.

AstraZeneca Pharmaceuticals LP accounted for 55.8% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 24 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.

GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trelegy Ellipta by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$261,435.73

401 reported records · 20 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
AstraZeneca Pharmaceuticals LP Unresolved — no canonical attribution shown $145,769.1155.8%1852025
GENZYME CORPORATION Unresolved — no canonical attribution shown $60,057.5323.0%522025
Regeneron Healthcare Solutions, Inc. Unresolved — no canonical attribution shown $43,130.1416.5%652025
GlaxoSmithKline, LLC. Unresolved — no canonical attribution shown $9,315.513.6%382025
Incyte Corporation Unresolved — no canonical attribution shown $1,752.150.7%22025
Genentech USA, Inc. Unresolved — no canonical attribution shown $373.000.1%102025
ARS Pharmaceuticals Operations, Inc. Unresolved — no canonical attribution shown $298.090.1%222025
Genentech, Inc. Unresolved — no canonical attribution shown $149.160.1%22025
Novartis Pharmaceuticals Corporation Unresolved — no canonical attribution shown $128.800.1%72025
CSL Behring Unresolved — no canonical attribution shown $105.960.0%42025
SANOFI-AVENTIS U.S. LLC Unresolved — no canonical attribution shown $94.990.0%12025
Grifols USA, LLC Unresolved — no canonical attribution shown $61.380.0%22025
Takeda Pharmaceuticals U.S.A., Inc. Unresolved — no canonical attribution shown $54.600.0%32025
Ionis Pharmaceuticals, Inc. Unresolved — no canonical attribution shown $36.530.0%22025
Optinose US, Inc. Unresolved — no canonical attribution shown $23.310.0%12025
Verona Pharma, Inc. Unresolved — no canonical attribution shown $22.880.0%12025
BioCryst US Sales Co., LLC Unresolved — no canonical attribution shown $18.250.0%12025
Galderma Laboratories, L.P. Unresolved — no canonical attribution shown $15.470.0%12025
PFIZER INC. Unresolved — no canonical attribution shown $14.810.0%12025
Amgen Inc. Unresolved — no canonical attribution shown $14.060.0%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program$226,027.6489
Travel and Lodging$22,318.8682
Food and Beverage$7,918.43224
Consulting Fee$5,006.004
Education$164.802

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
DUPIXENT
Normalized: dupixent		 Biological GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc., SANOFI-AVENTIS U.S. LLC $89,283.54 107 2025
Source payment records
AIRSUPRA
Normalized: airsupra		 Drug AstraZeneca Pharmaceuticals LP $68,177.21 79 2025
Source payment records
TEZSPIRE
Normalized: tezspire		 Biological Amgen Inc., AstraZeneca Pharmaceuticals LP $64,310.54 81 2025
Source payment records
FASENRA
Normalized: fasenra		 Biological AstraZeneca Pharmaceuticals LP $13,361.19 22 2025
Source payment records
NUCALA
Normalized: nucala		 Biological GlaxoSmithKline, LLC. $9,218.56 27 2025
Source payment records
XOLAIR
Normalized: xolair		 Biological, Drug Genentech USA, Inc., Genentech, Inc., Novartis Pharmaceuticals Corporation $536.67 13 2025
Source payment records
NEFFY
Normalized: neffy		 Drug ARS Pharmaceuticals Operations, Inc. $298.09 22 2025
Source payment records
BREZTRI
Normalized: breztri		 Drug AstraZeneca Pharmaceuticals LP $189.20 5 2025
Source payment records
TRELEGY ELLIPTA
Normalized: trelegy ellipta		 Drug GlaxoSmithKline, LLC. $96.95 11 2025
Source payment records
Rhapsido
Normalized: rhapsido		 Drug Novartis Pharmaceuticals Corporation $75.34 4 2025
Source payment records
Prolastin-C Liquid
Normalized: prolastin c liquid		 Biological Grifols USA, LLC $61.38 2 2025
Source payment records
TAKHZYRO
Normalized: takhzyro		 Biological Takeda Pharmaceuticals U.S.A., Inc. $54.60 3 2025
Source payment records
Hizentra
Normalized: hizentra		 Biological CSL Behring $48.44 2 2025
Source payment records
Andembry
Normalized: andembry		 Biological CSL Behring $33.42 1 2025
Source payment records
Haegarda
Normalized: haegarda		 Biological CSL Behring $24.10 1 2025
Source payment records
Xhance
Normalized: xhance		 Drug Optinose US, Inc. $23.31 1 2025
Source payment records
Ohtuvayre
Normalized: ohtuvayre		 Drug Verona Pharma, Inc. $22.88 1 2025
Source payment records
AYVAKIT
Normalized: ayvakit		 Biological GENZYME CORPORATION $20.68 1 2025
Source payment records
DONIDALORSEN
Normalized: donidalorsen		 Drug Ionis Pharmaceuticals, Inc. $18.45 1 2025
Source payment records
ORLADEYO
Normalized: orladeyo		 Drug BioCryst US Sales Co., LLC $18.25 1 2025
Source payment records
DAWNZERA
Normalized: dawnzera		 Drug Ionis Pharmaceuticals, Inc. $18.08 1 2025
Source payment records
NEMLUVIO
Normalized: nemluvio		 Drug Galderma Laboratories, L.P. $15.47 1 2025
Source payment records
CUTAQUIG
Normalized: cutaquig		 Biological PFIZER INC. $14.81 1 2025
Source payment records
PANZYGA
Normalized: panzyga		 Biological PFIZER INC. $14.81 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments productPayment yearPart D brandPart D yearClaimsMatch methodSource
TRELEGY ELLIPTA
trelegy ellipta		 2025 Trelegy Ellipta 2024 34
Beneficiary count suppressed		 exact normalized Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying companyPayment yearDrug reported by same entityOpen Payments evidencePart DClaimsBeneficiaries
AstraZeneca Pharmaceuticals LP
Exact reporting entity; no affiliate inference		 2025 SYMBICORT
open payments reported associated product		 CMS Open Payments — General Payments
71 supporting records · 51 recipient NPIs · example record 1206132610 		Symbicort · 2024
Exact normalized brand match · 1 Part D row		 15 suppressed by CMS
GlaxoSmithKline, LLC.
Exact reporting entity; no affiliate inference		 2025 TRELEGY ELLIPTA
open payments reported associated product		 CMS Open Payments — General Payments
131532 supporting records · 37148 recipient NPIs · example record 1190332369 		Trelegy Ellipta · 2024
Exact normalized brand match · 1 Part D row		 34 suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
Montelukast SodiumMontelukast Sodium14544
Azelastine HclAzelastine Hcl12341
Fluticasone PropionateFluticasone Propionate6829
EpinephrineEpinephrine6251
Dupixent PenDupilumab44suppressed
Breztri AerosphereBudesonide/Glycopyr/Formoterol37suppressed
Ipratropium BromideIpratropium Bromide3616
Albuterol Sulfate HfaAlbuterol Sulfate3524
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34suppressed
Arnuity ElliptaFluticasone Furoate32suppressed
Levocetirizine DihydrochlorideLevocetirizine Dihydrochloride31suppressed
Pantoprazole SodiumPantoprazole Sodium26suppressed
PrednisonePrednisone2422
Breo ElliptaFluticasone/Vilanterol21suppressed
Wixela InhubFluticasone Propion/Salmeterol21suppressed
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav1514
SymbicortBudesonide/Formoterol Fumarate15suppressed
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13suppressed
Triamcinolone AcetonideTriamcinolone Acetonide13suppressed
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $261,435.73 · 401 records AstraZeneca Pharmaceuticals LP AIRSUPRA, AYVAKIT, Andembry, BREZTRI, CUTAQUIG, DAWNZERA, DONIDALORSEN, DUPIXENT, FASENRA, Haegarda, Hizentra, NEFFY, NEMLUVIO, NUCALA, ORLADEYO, Ohtuvayre, PANZYGA, Prolastin-C Liquid, Rhapsido, TAKHZYRO, TEZSPIRE, TRELEGY ELLIPTA, XOLAIR, Xhance 2 —
2024 — — — — Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error